

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

SK-MEL-28

RRID:CVCL_0526

Type: Cell Line

Proper Citation

RRID:CVCL_0526

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0526

Proper Citation: RRID:CVCL_0526

Description: Cell line SK-MEL-28 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Cutaneous melanoma

Defining Citation: [PMID:313568](#), [PMID:327080](#), [PMID:978138](#), [PMID:1067619](#), [PMID:1716514](#), [PMID:2041050](#), [PMID:2068080](#), [PMID:2983346](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:6197381](#), [PMID:6203018](#), [PMID:6349783](#), [PMID:6582512](#), [PMID:6864164](#), [PMID:6933476](#), [PMID:7017212](#), [PMID:7175440](#), [PMID:7718330](#), [PMID:7999427](#), [PMID:8631022](#), [PMID:9331090](#), [PMID:9354451](#), [PMID:9466661](#), [PMID:9598804](#), [PMID:10700174](#), [PMID:10766161](#), [PMID:11016658](#), [PMID:11121133](#), [PMID:12068308](#), [PMID:12479222](#), [PMID:14692828](#), [PMID:14871852](#), [PMID:15009714](#), [PMID:15299072](#), [PMID:15467732](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:17260012](#), [PMID:17308088](#), [PMID:17363583](#), [PMID:17516929](#), [PMID:18277095](#), [PMID:18790768](#), [PMID:19147755](#), [PMID:19372543](#), [PMID:19799798](#), [PMID:20041153](#), [PMID:20164919](#), [PMID:20406486](#), [PMID:21424129](#), [PMID:21725359](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:23285177](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24576830](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25950383](#), [PMID:25960936](#), [PMID:26405815](#), [PMID:26589293](#), [PMID:26673621](#), [PMID:27087056](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:29492214](#), [PMID:30674989](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Characteristics: Lightly pigmented., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia -

CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SK-MEL-28

Synonyms: SK-Mel-28, SK.MEL.28, SK-MEL 28, SK MEL-28, SK MEL 28, SK Mel 28, SKMel-28, SKMEL-28, SK-MEL28, SK-Mel28, SK Mel28, SKMEL28, SKMel28, SKmel28, SKML-28, SK28, AU-Mel, P-36, P36

Cross References: BTO:BTO_0002131, CLO:CLO_0009043, EFO:EFO_0003081, MCCL:MCC:0000426, CLDB:cl4321, CLDB:cl4954, AddexBio:C0020001/66, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-72, BCRJ:0289, BioSample:SAMN03470899, BioSample:SAMN03472092, BioSample:SAMN03472754, BioSample:SAMN10987689, cancercellines:CVCL_0526, CancerTools:161917, Cell_Model_Passport:SIDM00081, CGH-DB:9317-4, ChEMBL-Cells:ChEMBL3308494, ChEMBL-Targets:ChEMBL614919, CLS:300337, Cosmic:686472, Cosmic:686476, Cosmic:687442, Cosmic:706106, Cosmic:721824, Cosmic:851050, Cosmic:874384, Cosmic:874446, Cosmic:875887, Cosmic:886831, Cosmic:888846, Cosmic:897491, Cosmic:898252, Cosmic:905230, Cosmic:905954, Cosmic:928748, Cosmic:932712, Cosmic:933135, Cosmic:974072, Cosmic:974262, Cosmic:1006554, Cosmic:1007156, Cosmic:1022271, Cosmic:1045407, Cosmic:1047687, Cosmic:1054859, Cosmic:1067227, Cosmic:1092633, Cosmic:1102386, Cosmic:1109809, Cosmic:1132589, Cosmic:1155280, Cosmic:1155570, Cosmic:1175872, Cosmic:1183772, Cosmic:1187579, Cosmic:1221590, Cosmic:1238109, Cosmic:1295337, Cosmic:1303055, Cosmic:1305368, Cosmic:1312350, Cosmic:1425350, Cosmic:1458966, Cosmic:1459645, Cosmic:1477319, Cosmic:1477408, Cosmic:1507598, Cosmic:1598350, Cosmic:1665022, Cosmic:1669144, Cosmic:1995635, Cosmic:1998476, Cosmic:2159448, Cosmic:2479251, Cosmic:2560253, Cosmic:2651877, Cosmic-CLP:905954, DepMap:ACH-000615, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:905954, GEO:GSM2115, GEO:GSM50205, GEO:GSM50267, GEO:GSM156050, GEO:GSM171012, GEO:GSM188226, GEO:GSM188256, GEO:GSM188315, GEO:GSM206543, GEO:GSM228378, GEO:GSM274690, GEO:GSM276739, GEO:GSM743468, GEO:GSM750825, GEO:GSM784506, GEO:GSM799357, GEO:GSM799420, GEO:GSM844690, GEO:GSM847116, GEO:GSM887584, GEO:GSM888667, GEO:GSM952581, GEO:GSM1138790, GEO:GSM1153427, GEO:GSM1153428, GEO:GSM1181282, GEO:GSM1181283, GEO:GSM1588919, GEO:GSM1670439, GEO:GSM1671969, GEO:GSM1671970, GEO:GSM1671974, GEO:GSM1671983, GEO:GSM1671986, GEO:GSM1671991, GEO:GSM1671996, GEO:GSM1672002, GEO:GSM1672006, GEO:GSM1672032, GEO:GSM1672043, GEO:GSM1672047, GEO:GSM1672049, GEO:GSM1672050, GEO:GSM1672054, GEO:GSM1672056, GEO:GSM1672060, GEO:GSM1672061, GEO:GSM2124651, GEO:GSM3039512, IARC_TP53:26113, ICLC:HTL99010, LiGeA:CCLE_529, LINCS_HMS:51101, LINCS_LDP:LCL-2092, NCI-DTP:SK-MEL-28, PharmacDB:SKMEL28_1396_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD007000, PRIDE:PXD030304, Progenetix:CVCL_0526, PubChem_Cell_line:CVCL_0526, RCB:RCB1930, SKY/M-FISH/CGH:2745, TKG:TKG 0333, Wikidata:Q54954013

ID: CVCL_0526

Record Creation Time: 20220427T221546+0000

Record Last Update: 20260829T235929+0000

Ratings and Alerts

No rating or validation information has been found for SK-MEL-28.

Warning: Discontinued: RCB; RCB1930

Characteristics: Lightly pigmented., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Warning: Discontinued: TKG; TKG 0333

Characteristics: Lightly pigmented., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 919 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Deng C, et al. (2026) Dysregulation of the PATZ1/CTCF Balance Silences ZBTB20 to Drive Melanoma Progression. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(26), e20917.

Lan TH, et al. (2026) A single-component optogenetic toolkit for reversible visualization and programmable control of microtubule dynamics. Cell reports methods, 101532.

Zhou Z, et al. (2026) The lipid-metabolic enzyme HSD17B12 drives lysosomal degradation of PD-L1 potentiating anti-tumor immunity in a mouse model. PLoS biology, 24(1), e3003603.

Shi HZ, et al. (2026) BGN/MDK Axis in the Melanoma Tumor Microenvironment Strengthens Tumor Malignancy by Modulating Cancer Cells and Cancer-Associated Fibroblasts Crosstalk. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(28), e14590.

Arroyo Villora S, et al. (2026) A Bioinformatics and Wet-Lab-Based Pipeline Identifies CLDN10 and GJB2 as Epigenetically Silenced Tumor Suppressor Genes in Cutaneous Melanoma. International journal of molecular sciences, 27(5).

Tang X, et al. (2026) Mathematical modeling of ribosome competition informs testable treatment strategies for drug-tolerant cancer persister cells. *iScience*, 29(4), 115493.

Cinel VDP, et al. (2026) Proteasomal degradation of intracellularly expressed Amblyomin-X limits suicide gene therapy potential in melanoma cells. *FEBS open bio*, 16(8), 1602.

Ramírez-Sánchez A, et al. (2026) Metabolic buffering restricts phenotype switching in melanoma. *The EMBO journal*.

de Blas A, et al. (2026) Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity. *Cancer research*, 86(12), 2896.

Cobb DA, et al. (2026) γ 3 CAR-T Cells Simultaneously Targeting Tumor and Metastases Produce Highly Effective Control in Preclinical Models of Melanoma and Triple-Negative Breast Cancer. *Molecular cancer therapeutics*, 25(7), 1181.

Mao C, et al. (2026) Driver Mutation Subtypes Differentially Shape Immune Evasion Landscapes in Melanoma: An AI-Driven Inflammatory Pathway Model Implicating CCNE1. *Human mutation*, 2026, 6776070.

Berra C, et al. (2026) AhR-dependent ferroptosis as a therapeutic opportunity to counteract BRAFi-resistance in melanoma. *Cell death discovery*, 12(1).

Ibrahim M, et al. (2026) NF1 Loss Remodels Tumor Niches for Immune Evasion. *bioRxiv : the preprint server for biology*.

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. *Cell reports. Medicine*, 7(4), 102694.

Zhao T, et al. (2025) Derepressing nuclear pyruvate dehydrogenase induces therapeutic cancer cell reprogramming. *Cell metabolism*, 37(8), 1667.

Kasama H, et al. (2025) Laeverin is Cell-Surface Target for Liquid-Phase Metastasizing Cancer Cells. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(47), e11349.

Vax E, et al. (2025) A novel Frizzled 7 antibody disrupts the Wnt pathway and inhibits Wilms tumor growth. *Frontiers in bioengineering and biotechnology*, 13, 1641137.

Iozzo M, et al. (2025) Sex-related changes in lactate dehydrogenase A expression differently impact the immune response in melanoma. *The FEBS journal*, 292(12), 3056.

Wiedmer T, et al. (2025) Metabolic mapping of the human solute carrier superfamily. *Molecular systems biology*, 21(6), 560.

Deuschmeyer VE, et al. (2025) SIAH3 is frequently epigenetically silenced in cancer and regulates mitochondrial metabolism. *International journal of cancer*, 156(2), 353.